Eli Lilly partners with AI startup Profluent to develop next-generation gene editors
Eli Lilly announced a collaboration with AI-focused biotech Profluent to create advanced gene-editing tools that could insert whole genes into patients.
The partnership is intended to move beyond traditional CRISPR approaches by using enzymes designed with artificial intelligence, potentially widening the scope of diseases that can be addressed.
Financial details were not fully disclosed, but the agreement may include up to $2.25 billion in milestone payments if all programs succeed. The deal aligns with Lilly's broader strategy to expand into genetic medicine, following recent acquisitions and the launch of a genetics center in Boston.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Eli Lilly enlists AI startup for next-generation gene editors”
read at STAT ↗
comments(0)
5-min edit window · permanent after that